| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MLLT6 |
| Uniprot No | P55198 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-462 aa |
| 活性数据 | MGAVNPLLSQAESSHTEPDLEDCSFRCRGTSPQESLSSMSPISSLPALFDQTASAPCGGGQLDPAAPGTTNMEQLLEKQGDGEAGVNIVEMLKALHALQKENQRLQEQILSLTAKKERLQILNVQLSVPFPALPAALPAANGPVPGPYGLPPQAGSSDSLSTSKSPPGKSSLGLDNSLSTSSEDPHSGCPSRSSSSLSFHSTPPPLPLLQQSPATLPLALPGAPAPLPPQPQNGLGRAPGAAGLGAMPMAEGLLGGLAGSGGLPLNGLLGGLNGAAAPNPASLSQAGGAPTLQLPGCLNSLTEQQRHLLQQQEQQLQQLQQLLASPQLTPEHQTVVYQMIQQIQQKRELQRLQMAGGSQLPMASLLAGSSTPLLSAGTPGLLPTASAPPLLPAGALVAPSLGNNTSLMAAAAAAAAVAAAGGPPVLTAQTNPFLSLSGAEGSGGGPKGGTADKGASANQEKG |
| 分子量 | 76.56 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MLLT6蛋白的3-4篇参考文献的简要列举：
1. **"MLLT6 maintains lineage-specific transcription and super-enhancers in acute myeloid leukemia"**
- **作者**: Shi J, et al. (2016)
- **摘要**: 研究揭示了MLLT6在急性髓系白血病(AML)中通过维持染色质开放性和超级增强子活性来调控白血病相关基因(如HOXA9)的转录，实验中利用重组MLLT6蛋白验证其与染色质调控复合物的相互作用。
2. **"Structural and functional characterization of the MLLT6 YEATS domain in histone recognition"**
- **作者**: Wu H, et al. (2017)
- **摘要**: 本文解析了MLLT6蛋白YEATS结构域的晶体结构，发现其通过特异性识别组蛋白H3的乙酰化修饰位点(如H3K27ac)，重组MLLT6蛋白的功能分析支持其在表观遗传调控中的作用。
3. **"MLLT6 interacts with multiple chromatin modifiers to regulate oncogenic transcriptional programs"**
- **作者**: Rousseaux S, et al. (2014)
- **摘要**: 研究通过重组MLLT6蛋白的体外结合实验，发现其与MLL1、DOT1L等多种染色质修饰酶形成复合物，协同调控靶基因(如MEIS1)在白血病中的异常表达。
4. **"Proteomic analysis identifies MLLT6 as a critical regulator of MYC-driven cancer progression"**
- **作者**: Zhang Y, et al. (2018)
- **摘要**: 利用重组MLLT6蛋白和基因编辑技术，研究揭示了MLLT6通过稳定MYC蛋白促进多种癌症(如乳腺癌、结肠癌)的进展，机制涉及对泛素化降解通路的抑制。
---
**说明**：以上文献均为虚构示例，实际需通过PubMed或Web of Science等平台检索。若需具体文献，建议使用关键词“MLLT6”、“AF17q21”、“YEATS domain”或“chromatin complex”进行筛选。
MLLT6 (Mixed-Lineage Leukemia Translocated To, 6), also known as AF17. is a nuclear protein encoded by the MLLT6 gene located on chromosome 17q12. It is a member of the SEC (Super Elongation Complex) family and plays a critical role in transcriptional regulation, particularly in RNA polymerase II-mediated transcription elongation. Structurally, MLLT6 contains conserved domains such as the YEATS domain, which facilitates binding to histones and other chromatin-associated proteins, enabling epigenetic modulation.
Originally identified as a partner gene in MLL (Mixed-Lineage Leukemia) chromosomal translocations linked to acute leukemias, MLLT6 fusion proteins (e.g., MLL-MLLT6) disrupt normal transcriptional control, driving oncogenesis by dysregulating genes involved in cell proliferation and differentiation. Beyond leukemia, MLLT6 participates in diverse cellular processes, including DNA repair, chromatin remodeling, and cell cycle regulation. It interacts with key regulators like DOT1L histone methyltransferase to modulate histone H3K79 methylation, influencing gene expression.
Recombinant human MLLT6 protein is produced via expression systems (e.g., E. coli, mammalian cells) for functional studies, structural analysis, and drug screening. Its applications span investigating transcriptional mechanisms, leukemia pathogenesis, and developing targeted therapies. Research continues to explore its role in cancers and potential as a biomarker or therapeutic target, highlighting its dual significance in basic biology and clinical contexts.
×
